Literature DB >> 33879872

Prodromal Parkinson disease subtypes - key to understanding heterogeneity.

Daniela Berg1, Per Borghammer2,3, Seyed-Mohammad Fereshtehnejad4,5,6, Sebastian Heinzel7, Jacob Horsager2, Eva Schaeffer7, Ronald B Postuma4,8,9.   

Abstract

In Parkinson disease (PD), pathological processes and neurodegeneration begin long before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal phase, risk and prodromal markers can be used to identify individuals who are likely to develop PD, as in the recently updated International Parkinson and Movement Disorders Society research criteria for prodromal PD. However, increasing evidence suggests that clinical and prodromal PD are heterogeneous, and can be classified into subtypes with different clinical manifestations, pathomechanisms and patterns of spatial and temporal progression in the CNS and PNS. Genetic, pathological and imaging markers, as well as motor and non-motor symptoms, might define prodromal subtypes of PD. Moreover, concomitant pathology or other factors, including amyloid-β and tau pathology, age and environmental factors, can cause variability in prodromal PD. Patients with REM sleep behaviour disorder (RBD) exhibit distinct patterns of α-synuclein pathology propagation and might indicate a body-first subtype rather than a brain-first subtype. Identification of prodromal PD subtypes and a full understanding of variability at this stage of the disease is crucial for early and accurate diagnosis and for targeting of neuroprotective interventions to ensure efficacy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33879872     DOI: 10.1038/s41582-021-00486-9

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  139 in total

Review 1.  MDS clinical diagnostic criteria for Parkinson's disease.

Authors:  Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

2.  Depression and subsequent risk of Parkinson disease: A nationwide cohort study.

Authors:  Helena Gustafsson; Anna Nordström; Peter Nordström
Journal:  Neurology       Date:  2015-05-20       Impact factor: 9.910

3.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.

Authors:  Seyed-Mohammad Fereshtehnejad; Silvia Rios Romenets; Julius B M Anang; Véronique Latreille; Jean-François Gagnon; Ronald B Postuma
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

4.  Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.

Authors:  Eduardo De Pablo-Fernández; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

5.  Medical records documentation of constipation preceding Parkinson disease: A case-control study.

Authors:  R Savica; J M Carlin; B R Grossardt; J H Bower; J E Ahlskog; D M Maraganore; A E Bharucha; W A Rocca
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

6.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study.

Authors:  Anette Schrag; Laura Horsfall; Kate Walters; Alastair Noyce; Irene Petersen
Journal:  Lancet Neurol       Date:  2014-11-27       Impact factor: 44.182

Review 7.  Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Bastiaan Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda M Halliday; John Hardy; Anthony E Lang; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2014-03-11       Impact factor: 10.338

8.  Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

Authors:  Hirotaka Iwaki; Cornelis Blauwendraat; Hampton L Leonard; Ganqiang Liu; Jodi Maple-Grødem; Jean-Christophe Corvol; Lasse Pihlstrøm; Marlies van Nimwegen; Samantha J Hutten; Khanh-Dung H Nguyen; Jacqueline Rick; Shirley Eberly; Faraz Faghri; Peggy Auinger; Kirsten M Scott; Ruwani Wijeyekoon; Vivianna M Van Deerlin; Dena G Hernandez; Aaron G Day-Williams; Alexis Brice; Guido Alves; Alastair J Noyce; Ole-Bjørn Tysnes; Jonathan R Evans; David P Breen; Karol Estrada; Claire E Wegel; Fabrice Danjou; David K Simon; Bernard Ravina; Mathias Toft; Peter Heutink; Bastiaan R Bloem; Daniel Weintraub; Roger A Barker; Caroline H Williams-Gray; Bart P van de Warrenburg; Jacobus J Van Hilten; Clemens R Scherzer; Andrew B Singleton; Mike A Nalls
Journal:  Neurol Genet       Date:  2019-07-09

9.  Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI.

Authors:  Seyed-Ahmad Ahmadi; Kai Bötzel; Johannes Levin; Juliana Maiostre; Tassilo Klein; Wolfgang Wein; Verena Rozanski; Olaf Dietrich; Birgit Ertl-Wagner; Nassir Navab; Annika Plate
Journal:  Neuroimage Clin       Date:  2020-02-01       Impact factor: 4.881

Review 10.  The clinical heterogeneity of Parkinson's disease and its therapeutic implications.

Authors:  Julia C Greenland; Caroline H Williams-Gray; Roger A Barker
Journal:  Eur J Neurosci       Date:  2018-10-14       Impact factor: 3.386

View more
  29 in total

Review 1.  Magnetic Resonance Imaging Studies of Neurodegenerative Disease: From Methods to Translational Research.

Authors:  Peiyu Huang; Minming Zhang
Journal:  Neurosci Bull       Date:  2022-06-30       Impact factor: 5.203

Review 2.  Neuroinflammation and Immune Changes in Prodromal Parkinson's Disease and Other Synucleinopathies.

Authors:  Miriam Højholt Terkelsen; Ida H Klaestrup; Victor Hvingelby; Johanne Lauritsen; Nicola Pavese; Marina Romero-Ramos
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 3.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

Review 4.  Gastrointestinal mucosal biopsies in Parkinson's disease: beyond alpha-synuclein detection.

Authors:  Pascal Derkinderen; François Cossais; Adrien de Guilhem de Lataillade; Laurène Leclair-Visonneau; Michel Neunlist; Sébastien Paillusson; Roberto De Giorgio
Journal:  J Neural Transm (Vienna)       Date:  2021-11-24       Impact factor: 3.850

5.  The Discovery of α-Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution.

Authors:  Naomi P Visanji; Gabor G Kovacs; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2021-08-23

6.  Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model.

Authors:  Christopher Käufer; Cara S Schreiber; Anna-Sophia Hartke; Ivo Denden; Stephanie Stanelle-Bertram; Sebastian Beck; Nancy Mounogou Kouassi; Georg Beythien; Kathrin Becker; Tom Schreiner; Berfin Schaumburg; Andreas Beineke; Wolfgang Baumgärtner; Gülsah Gabriel; Franziska Richter
Journal:  EBioMedicine       Date:  2022-04-16       Impact factor: 11.205

Review 7.  Air Pollution and the Risk of Parkinson's Disease: A Review.

Authors:  Hiromi Murata; Lisa M Barnhill; Jeff M Bronstein
Journal:  Mov Disord       Date:  2022-01-19       Impact factor: 9.698

Review 8.  Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.

Authors:  Honglei Chen; Keran Wang; Filip Scheperjans; Bryan Killinger
Journal:  Neurobiol Dis       Date:  2021-12-23       Impact factor: 7.046

Review 9.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

10.  Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies.

Authors:  Lisanne J Dommershuijsen; Agnita J W Boon; M Kamran Ikram
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.